Translational relevance
There is a pressing need for in vivo diagnostic imaging techniques that non-invasively measure expression of the immune checkpoint protein hPD-L1 in tumors. Such tracers could identify prospective patient responders to immune checkpoint blockade therapy at an earlier stage, thereby potentially improving treatment outcomes. In this article we present the development of a novel 12-kDa small protein scaffold of a fibronectin type 3 domain (FN3)
binder that targets hPD-L1, which is expressed in most human tumors. We radiolabeled the binder, as 64 Cu-FN3 hPD-L1 , for PET imaging. The radiotracer was evaluated in three groups of NSG mice, bearing hPD-L1-positive (with/without blocking) syngeneic or hPD-L1-negative xenograft tumors. Early assessment of tracer uptake revealed increased tumor-to-muscle ratios of 5.6±0.9 and 13.1±2.3 at 1 and 4 hours post-injection, respectively. In addition, FN3 hPD-L1 bound hPD-L1 in human cancer tissues that were also evaluated with validated hPD-L1 antibodies, indicating the potential for clinical translation of this radiotracer. 
INTRODUCTION
Despite multiple mechanisms employed by cancer cells to evade and inhibit the host tissue's immunological surveillance (1), many treatment strategies based on antagonizing coinhibitory, or activating co-stimulatory, pathways of immune cells have emerged (2) . Clinical studies based on targeting these pathways clearly indicate prolonged patient survival by [6] [7] [8] [9] [10] [11] [12] months (3, 4) . In particular, the targeting of immune checkpoints (ICs) such as programmed death receptor-1 (PD-1, CD279) and its ligand PD-L1 (B7-H1, CD274), and anti-CTLA-4 therapy is rapidly advancing the field of cancer immunotherapy.
In the case of PD-1/PD-L1 immune checkpoint inhibitor therapy (5) , PD-1 is expressed on activated T, B, and natural killer lymphocytes whereas PD-L1 is expressed in a wide variety of tumors including melanoma, non-small cell lung cancer, Merkel cell carcinoma, breast cancer, and squamous cell carcinoma (4, 6) . PD-L1 is also expressed on the surface of macrophages, endothelial cells, and other nonmalignant tissues (e.g. pancreatic), which aids in the prevention of autoimmune disease (7, 8) .
In the tumor microenvironment, PD-L1 expression is mainly promoted by the adaptive immune response mechanisms to interferon-γ (IFN-γ) secreted by antigen-bound tumorinfiltrating T cells (8, 9) . KRAS and PTEN gene mutations (9p24.1) in certain tumors also promote PD-L1 expression (10, 11) . The overall role of PD-L1 expression by tumors is to inhibit activation of infiltrating PD-1-expressing cytotoxic T cells, thereby evading the host immune system and suppressing its response (12) .
In current clinical practice, the decision to proceed with IC inhibitor therapy with anti-
PD-L1 immunotherapy is based on anti-PD-L1 immunohistochemistry (IHC) staining in biopsied
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Author Manuscript Published OnlineFirst on October 29, 2018 ; DOI: 10.1158/1078-0432.CCR- tumor tissue sections (13, 14) . The amount of PD-L1 expression is also used as a surrogate for determining whether a patient might respond to anti-PD-1 immunotherapy (15) . Although IHC is a well-established technique that undergoes rigorous validation prior to clinical utilization, numerous factors may contribute to inconsistent results: a) under-or mis-sampling of the tumor region with the highest PD-L1 expression at the time of biopsy, b) difficulty in obtaining adequate specimens in patients with metastatic disease, and c) variability in baseline biomarker expression due to previous anti-cancer therapies. Further, IHC lacks the spatial and temporal resolution of the biomarker expression profile within the entire tumor. On the other hand, noninvasive PET imaging allows repetitive visualization of PD-L1-expressing tumors throughout the body that enables improved lesion localization and characterization (16, 17) .
Many pre-clinical studies have shown that PD-L1 expression in tumors can be assessed by PET imaging (18) (19) (20) . However, antibody-based PD-L1 tracer imaging studies suffer from slow clearance of the antibodies from the non-target tissues and limit the use of shorter half-life radioisotopes for labeling. For diagnostic imaging, tracers with faster clearance profiles from non-target tissues would enable quantitation of the signals from the target tissues at earlier time points (e.g. 1-4 hours post injection [p.i]). This can be achieved using small proteins (~25-50 kDa) or nanobodies (~10 kDa), a class of molecules that can be imaged in target tissue within 4 hours of administration. Such an approach would be more patient-friendly (for example the patient would not have to return the day after radiotracer injection for PET imaging) and expedite the initiation of the appropriate IC therapy. We have previously developed a class of protein scaffolds, e.g. the tenth type III domain of human fibronectin (FN3, ~10 kDa) as a platform that can provide faster clearance (<12 hours vs. ~72 hours in the case of antibodies) and demonstrates a specific in vivo targeting ability to yield excellent tumor-to-background contrast (24) .
FN3 has been engineered for many targets (22, 23) with picomolar to nanomolar affinity, including molecular imaging of cancer using PET in murine models (24) and in phase II clinical studies in therapeutic oncology (25) . FN3 demonstrates a high stability scaffold, contains three solvent-exposed loops that can be mutated to introduce new high-affinity variants, and a single lysine that provides rapid amine conjugation of chelators (23, 26, 27) . Similar kinds of molecules that have already been validated for clinical use include affibodies (21, 28) , knottins (29) , nanobodies (30, 31) , peptides (32, 33) , and antibody fragments (34) (35) (36) . These small molecules are designed to enhance vascular extravasation (37) and tissue penetration for delivery into solid tumors (38, 39) .
Anti-hPD-L1 antibody (atezolizumab)-based imaging studies revealed that hPD-L1 can be detected in the tumor microenvironment using various isotopes ( 111 In, 64 Cu, and 89 Zr) in mouse tumor xenograft models (18) . In this report, we present the development of a novel small protein molecule PET tracer, 64 Cu-FN3 hPD-L1 , for imaging of hPD-L1 expression in an hPD-L1-expressing tumor mouse model at time points as early as 1-hour p.i. In human cancer tissue specimens, we further show a similarity between our FN3 hPD-L1 binder and two validated hPD-L1
antibodies in regard to detecting hPD-L1 expression status.
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MATERIALS and METHODS

Reagents and radiochemicals
All reagents were obtained from Sigma-Aldrich (St. Louis, MO) unless otherwise stated.
N-succinimidyl-DOTA (NHS-DOTA) was purchased from Macrocyclics (Plano, TX). The CT26 mouse colon carcinoma cells engineered to express human PD-L1 were authenticated by short tandem repeat profiling in Dr. Irving Weissman's lab, and kindly provided for this study. were maintained according to standard techniques and used within three passages. They were maintained in DMEM supplemented with 10% fetal calf serum, 2 mmol/L glutamine, 100 units/mL penicillin, 100 μg/mL streptomycin, and 0.25 μg/mL fungizone. Media and supplements were obtained from Life Technologies (Carlsbad, CA).
High-performance liquid chromatography (HPLC) was performed on HPLC-Ultimate (ThermoFisher, Waltham, MA) with an ultraviolet detector and an inline radioactivity detector.
The system used a SEC-2000 LC column (300 × 7.8 mm) with 5 μm hydrophilic bonded silica support and 400 Å pore size (Phenomenex, Torrance, CA). Matrix-assisted laser desorption ionization (MALDI) mass spectrometry was performed with a TOF/TOF TM 5800 (SCIEX,
Engineering of FN3 hPD-L1
The human PD-L1 (hPD-L1, or B7-H1, CD274) protein was purchased (catalogue # 10084-H02H-100, Sino Biologics, Beijing, P.R. China), biotinylated, characterized by MALDI, and immobilized on streptavidin magnetic beads for screening of FN3 binders. The yeast surface displayed FN3 G4 library with diversified loops and was sorted and matured as previously described (26, 40) . Briefly, yeast displaying 2.5×10 8 FN3 mutants were sorted for binding to magnetic beads with immobilized hPD-L1 protein, followed by fluorescence-activated cell sorting (FACS) for full-length proteins using the C-terminal c-myc epitope. Plasmid DNA from selected clones was recovered, mutated by error-prone PCR of either the entire FN3 gene or the paratope loops, and reintroduced into yeast by electroporation with homologous recombination.
As binder enrichment progressed in later evolutionary cycles, FACS for binding to soluble hPD-L1 protein was also used. Five cycles of selection and mutation were performed. Plasmid DNA was recovered, transformed into bacteria, and individual clones were sequenced by standard DNA sequencing methods. The best binder (FN3 hPD-L1 , Fig. 1A ) was expressed in bacterial culture with a His 6 tag, purified by nickel column chromatography, and reversed-phase HPLC (41) .
Preparation of FN3 hPD-L1
Bacterial expression plasmids were constructed to express FN3 hPD-L1. The plasmids also encoded for a C-terminal His 6 epitope tag for purification. Plasmids were transformed into BL21 Tween-20 and 1% bovine serum albumin (BSA), and sample plates were agitated at 1000 rpm.
Biotin-FN3 hPD-L1 was coupled onto streptavidin tips (Thermo Fisher Scientific, Waltham, MA).
hPD-L1 protein was titrated into 5-500 nmol/L binding sites using a 1.2-fold dilution series. The FN3 hPD-L1 binder was immobilized on a streptavidin coated-tip. These mixtures were allowed to bind the sensor tip-coupled FN3 binder for 10 minutes. We confirmed that neither hPD-L1
protein nor binder bound non-specifically to the unmodified tips. Samples were analyzed on duplicate tips to verify that the assay was reproducible between tips. Octet data were exported into Scrubber v.2.0a (BioLogic Software Pvt Ltd, Australia) for data processing and analysis. 
Preparation of Do-FN3 hPD-L1
The DOTA-NHS ligand has already shown good biological performance when used in protein conjugation of various radionuclides such as 68 Ga and 64 Cu ( 
Radiolabeling of Do-FN3 hPD-L1
64 CuCl 2 was received from the University of Wisconsin (Madison, WI) and its specific activity at the time of shipment (24 hours prior to labeling) was 1.6±0.2 Ci/μmol. Radiolabeling of Do-FN3 hPD-L1 was performed using 64 was filtered through a 0.2 μm filter into a sterile vial.
Radiotracer immunoreactivity assay
Immunoreactivity of the 64 Cu-FN3 hPD-L1 tracer was tested by cell-binding assays as previously described (41 PA). For each small animal PET scan, three-dimensional ROIs were drawn around the tumor, heart, liver, kidneys, and muscles on decay-corrected whole-body images. The tumor ROI analysis was performed in the same manner as that of the other organs (i.e., based on the anatomical information of the CT image in which organs and the tumor are well-delineated to enable drawing of the ROIs). The average radioactivity concentration in the ROI was obtained from the mean pixel values within the ROI volume. These data were converted to counts/mL/minute by using a predetermined conversion factor (41) . The results were then divided by the injected dose to obtain an image ROI-derived %ID/g.
Cancer patient tissue specimens
De-identified tissue sections from biopsies and corresponding subsequent resections of six cancer patients were obtained through a Stanford Institutional Review Board (IRB)-approved protocol (IRB-44051). The cases consisted of primary lung adenocarcinoma (n=2), metastatic lung adenocarcinoma to brain (n=3), and oncocytic thyroid carcinoma (n=1). Supplementary   Table S1 online summarizes the clinical characteristics of the patients from who the tissue sections were obtained.
Histology and immunofluorescence staining of hPD-L1
The human cancer tissues and implanted mouse xenografts (MDA-MB-231 and Raji) were obtained in paraffin-embedded blocks and sectioned into 4-5 µm-thick sections for 
Statistical Analyses
Data were analyzed and plotted using Prism version 5.01 (GraphPad Software Inc., La Jolla, CA). Data were tested for normality using the Shapiro-Wilk test. An unpaired two-tailed Student's t test was used to compare the means of groups of normally-distributed data. For nonnormally distributed data, the Wilcoxon rank-sum analysis of medians was performed. A p-value less than 0.05 was considered to be statistically significant. Bonferroni correction was used to adjust alpha for multiple comparisons. Data are presented as mean±standard deviation (SD).
RESULTS
Screening, selection, and binding affinity of FN3 hPD-L1
Based on the hPD-L1 cell binding study, the best unique clone against hPD-L1 protein was selected and called FN3 hPD-L1 . We performed the sequence analyses for confirmation of the full framework and uniqueness of the loop region. The soluble protein yield was >5mg/L with >95% purity by HPLC and demonstrated 11,826 Da molecular weight when measured by mass spectrometry (expected 11,824 Da). This soluble FN3 hPD-L1 binder was biotinylated to determine the binding affinity (one biotin per FN3 hPD-L1 molecule, as determined by MALDI spectrometry).
The purified soluble FN3 hPD-L1 binder displayed the dissociation constant (K d ) of 0.61±0.02 nmol/L for purified hPD-L1 (Fig. 1B) . A flow cytometry assay with live CT26/hPD-L1 cells indicated the binding affinity of FN3 hPD-L1 for cell surface hPD-L1 was 1.40.3 nmol/L (Fig. 1C) .
Synthesis and quality control of the 64 Cu-FN3 hPD-L1 radiotracer
The characterization of 64 Cu-FN3 hPD-L1 radiotracer is summarized in Table 1 . DOTA-NHS (Do) was conjugated to lysine groups of FN3 hPD-L1 and yielded Do-FN3 hPD-L1 with 1-2 chelates per binder, as confirmed by MALDI-TOF mass spectrometry ( Supplementary Fig. S2 online). This DOTA-conjugated FN3 hPD-L1 binder (Do-FN3 hPD-L1 ) was further purified using SEC2000-HPLC column and radiolabeled with 64 Cu. The final yield and purity of 64 Cu-FN3 hPD-L1 were greater than 70% and 95%, respectively (Fig. 2a) . SEC2000-HPLC showed that the specific activity of FN3 hPD-L1 was 5.3±0.5 GBq/µmol ( Table 1) . Immunoreactivity of the 64 Cu- 
Tumor-to-muscle ratio and ex vivo biodistribution of 64
Cu-FN3 hPD-L1 radiotracer in mice bearing syngeneic and xenograft tumors
We further calculated the tumor-to-muscle ratios of the PET signal at 1 and 4 hours p.i. in the CT26/hPD-L1-nblk, CT26/hPD-L1-blk, and Raji-nblk groups as %ID/g, after decaycorrection ( Figure 4a ). The tumor-to-muscle ratio of 64 Cu-FN3 hPD-L1 was significantly greater in the CT26/hPD-L1-nblk group compared to the corresponding blk group at both 1 hour p.i. 
hPD-L1 expression status in human cancer tissues based on validated naturally hPD-L1 antibodies and the FN3 hPD-L1 binder
To assess the translational potential of the FN3 hPD-L1 scaffold's ability to correctly identify the presence of hPD-L1 expression in human tissue, FN3 hPD-L1 binder immunofluorescence was compared to immunohistochemistry of the two validated hPD-L1
antibodies in tissue sections from six human cancer cases (Table S1 ). Supplementary Figure S4 displays the hPD-L1 expression status at the time of biopsy (based on the results from an FDAapproved send-out lab) and subsequent resection (using the two validated hPD-L1 antibodies and the FN3 hPD-L1 binder). Supplementary Figure S4 shows the heterogeneity of hPD-L1 expression not only from one patient to another, but also from biopsy to resection within the same patient. In the very low (<5%) hPD-L1 expressing cases (Cases 1-3, the two lung primary tumors and one of the metastatic lung to brain tumors) at the time of resection, there was 100% agreement among the two validated hPD-L1 antibodies and the FN3 hPD-L1 binder. In the remaining three cases with moderate-high (30-80%) hPD-L1 expression (Cases 4-6), the two validated antibodies resulted in comparable (i.e. within 5-15% of each other) hPD-L1 expression results. In these same three cases, the magnitude of hPD-L1 expression based on the FN3 hPD-L1 binder was lower but still ≥10% (Fig. S4) . Fig. 5 shows H&E, immunohistochemistry (using two validated hPD-L1 antibodies), and immunofluorescence (using the FN3 hPD-L1 binder) in representative low and high hPD-L1-expressing human cancer tissues (Cases 3 and 6, respectively). At these extrema, the FN3 hPD-L1 staining pattern demonstrated a similar trend compared with that of the two validated hPD-L1 antibodies.
hPD-L1 expression status in mice bearing xenografts of human tumors with different hPD-L1 levels (MDA-MB-231 and Raji), based on validated hPD-L1 antibodies
In the MDA-MB-231 xenograft that received 64 Cu-FN3 hPD-L1 (100 µCi / 10 µg of FN3 hPD-L1 binder), hPD-L1 staining with the validated antibodies was scored as 55% using clone E1L3N
and 85% using clone SP263 (Supplementary Figure S5C) . We also performed validated hPD-L1
antibody staining in MDA-MB-231 (hPD-L1 expressing) and Raji (hPD-L1 non-expressing) xenografts that were not exposed to 64 Cu-FN3 hPD-L1 (Supplementary Figure S6) . The MDA-MB-231 and Raji hPD-L1 expression was scored as 60% and 0%, respectively (clone E1L3N), and 90% and 5%, respectively (clone SP263).
DISCUSSION
In this report, we present the development of a novel radiotracer that targets hPD-L1, an immune checkpoint protein expressed in most tumors. The resulting FN3-based small protein binder of hPD-L1 (FN3 hPD-L1 ) , which was approximately one-tenth the size of an antibody, bound purified hPD-L1 protein and cells engineered to express hPD-L1 (19, 24, 41) . Whereas antibody-based tracers can take a few days to attain optimal tumor uptake and then be cleared from the background tissues (43), small protein binders can do so within 24 hours (29) . We made three molecular components (FN3 hPD-L1 binder, Do-FN3 hPD-L1 conjugate, and 64 Cu-FN3 hPD-L1 radiotracer), each of which was carefully assayed for its binding property against purified hPD-L1 protein (Figs. 1-2 ).
The pre-clinical in vivo imaging study revealed that the 64 Cu-FN3 hPD-L1 radiotracer rapidly targeted the tumors expressing hPD-L1 (Fig. 3) . In fact, this tracer provided a tumor-tomuscle ratio in the CT26/hPD-L1-nblk group that was 3-and 9-times greater than that in the group pre-injected with non-radioactive FN3 hPD-L1 (blk), as early as 1 and 4 hours post-injection, respectively (Figs. 3-4) . Further, we evaluated the specificity of the tracer in vivo under preblocking with nonradioactive FN3 hPD-L1 (blk) and pre-non-blocking (nblk) conditions in mice bearing hPD-L1-positive (CT26/hPD-L1) and hPD-L1-negative (Raji) tumors. The results indicated that the PET signals at 4 hours p.i. from the CT26/hPD-L1 tumors were substantially lower in the blk group compared to the nblk group by 6-fold (Figs. 3) .
Previously, we developed the hPD-L1-targeting 64 Cu-DOTA-HAC tracer and tested it in a NSG mouse model bearing CT26/hPD-L1 cells engineered to expresses hPD-L1 protein, which resulted in a moderate uptake of ~2 %ID/g at 1 hour p.i. (19 
tumor-to-muscle ratio of ~6. A protein binder's binding affinity is influenced by its binding domain, not its size (24) . As reported in (24, 40, 44) and the current study, the smaller the protein binder, the faster its clearance. For example, based on ROI analysis in a study by Olafsen Although the 64 Cu-FN3 hPD-L1 tracer showed excellent tumor uptake at early time points and rapid clearance from most non-target tissues, its elevated signals in the liver and kidney at 24 hours p.i. were of less concerning for two reasons. The liver activity may be due to dissociation of 64 Cu from DOTA (45) or charge effects of the engineered protein and the DOTA chelator.
Kidney retention is a common problem for small proteins (44) because they pass through the glomerulus and can be reabsorbed in the renal tubules. Although we observed increased uptake of 64 Cu-FN3 hPD-L1 in the kidneys compared to that in the tumors, such uptake is similar to that of many other comparable-sized 64 Cu-DOTA-labeled molecules (e.g. 64 Cu-anti-CD20 minibody) (44) . Over the first 4 hours after administration, the tracer uptake increased 38% in the tumor whereas it decreased by 16% in the kidney, suggesting renal clearance of the radiotracer (Fig. 3) .
On the other hand, in our previous study of a different class of binder derived from hPD-1 protein (high-affinity consensus [HAC]) (19) , the 64 Cu-DOTA-HAC radiotracer uptake decreased in both the tumor and kidney over the first four hours after administration, by 14% and 27%, respectively. Over the course of hPD-L1 tracer development in our laboratory, the 64 Cu-FN3 hPD-L1 radiotracer appears to have achieved improved tumor retention by 1.3-fold over the other binder class, HAC (19) .
The results of our study and others (18, 44, 46) demonstrate that smaller binders can provide improved imaging results compared to high molecular weight antibodies both in terms of tumor-to-background ratio and absolute tumor uptake at early time points after tracer injection has the potential for human translation to prospectively identify likely responders to immune checkpoint blockade therapy.
Conclusions
In conclusion, we developed and radiolabeled a novel 12 kDa FN3-based anti-hPD-L1 tracer ( 64 Cu-FN3 hPD-L1 ) for PET imaging of human PD-L1 expressed in a mouse colorectal carcinoma syngeneic tumor model. In addition, FN3 hPD-L1 was confirmed to bind hPD-L1 in human cancer tissue specimens with known hPD-L1 expression status based on validated hPD-L1 antibodies.
This indicates the potential for clinical translation of this radiotracer. Tables and Figures   Table   Table 1 post-injection. Organs were then isolated, and uptake of tracer dose was measured by gamma counter (decay-corrected mean %ID/g ±SD,). Pre-blocked mice (blk) received 10 mg/kg of nonradioactive FN3 hPD-L1 via tail vein 2 hours before 64 Cu-FN3 hPD-L1 radiotracer injection whereas non-blocked mice (nblk) did not. Immunoreactivity fraction 85%
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